Department of Pediatric Neurology, Guizhou Provincial People's Hospital, Guiyang, China.
Department of Otolaryngology, Guizhou Provincial People's Hospital, Guiyang, China.
Front Immunol. 2022 Feb 23;13:803854. doi: 10.3389/fimmu.2022.803854. eCollection 2022.
The aim of this study was to analyze the positive rate and test strategies of suspected autoimmune encephalitis (SAE) based on an antibody assay.
Patients who were diagnosed with suspected autoimmune encephalitis in Guizhou Province between June 1, 2020, and June 30, 2021 and who had anti-neuronal autoantibodies detected by Guizhou KingMed Diagnostics Group Co., Ltd. were included in this study. The positive rate and the test strategies were analyzed based on the results of the anti-neuronal antibody assay.
A total of 263 patients with SAE were included, 58.2% (153/263) of whom were males, with a median age of 33 years (1-84 years). 84% (221/263) of all patients completed both serum and CSF tests. A total of 46.0% (121/263) of SAE patients received the AE-6 examination package. The antibody-positive rate was 9.9% (26/263) in the current cohort, with an observed incidence of antibody positive of 0.2 in 100,000 (26/11,570,000, 95% CI: 0.15-0.30), and the estimated incidence was 0.9 in 100,000 (95% CI: 0.84-0.95) of the total population. A total of 9 different anti-neuronal antibodies were detected. Anti-NMDAR antibody was the most common antibody in 46.2% (12/26) of subjects, 70.0% (7/10) of whom were children, followed by anti-Caspr2 antibody in 30.8% (8/26); the remaining 7 antibodies were detected in 23.1% (6/26) of the population. There were no obvious differences among age, sex or season in the positive rate of anti-neuronal antibodies. The cost of antibody testing per capita was $439.30 (SD±$195.10). The total cost of AE-14 was the highest at $48.016.81 (41.56%) among all examination packages.
This study described the positive rate associated with AE-related anti-neuronal antibodies and test strategies in the current cohort, which provides a basis for clinicians in clinical practice.
本研究旨在分析基于抗体检测的疑似自身免疫性脑炎（SAE）的阳性率和检测策略。
纳入 2020 年 6 月 1 日至 2021 年 6 月 30 日期间在贵州省被诊断为疑似自身免疫性脑炎且在贵州金域医学检验中心有限公司检测到抗神经元自身抗体的患者。基于抗神经元抗体检测结果，分析阳性率和检测策略。
共纳入 263 例 SAE 患者，其中 58.2%（153/263）为男性，中位年龄为 33 岁（1-84 岁）。所有患者中，84%（221/263）均完成血清和脑脊液检测。263 例患者中，共有 46.0%（121/263）接受了 AE-6 检测包检测。本队列中抗体阳性率为 9.9%（26/263），抗体阳性观察发生率为 1/100,000（26/11,570,000，95%CI：0.15-0.30），估计发生率为 1/100,000（95%CI：0.84-0.95）。共检测到 9 种不同的抗神经元抗体。在 46.2%（12/26）的患者中，最常见的抗体是抗 NMDAR 抗体，其中 70.0%（7/10）为儿童，其次是抗 Caspr2 抗体，占 30.8%（8/26）；其余 7 种抗体在 23.1%（6/26）的人群中被检测到。神经元抗体的阳性率在年龄、性别或季节之间无明显差异。人均抗体检测费用为 439.30 美元（SD±195.10）。所有检测包中，AE-14 的检测费用最高，为 48016.81 美元（41.56%）。
本研究描述了当前队列中与 AE 相关的抗神经元抗体的阳性率和检测策略，为临床医生的临床实践提供了依据。
